Core Viewpoint - The company reported a significant decline in both revenue and net profit for the third quarter and the first three quarters of the year, indicating challenges in its business operations [1] Financial Performance - Q3 revenue was 2.629 billion yuan, a decrease of 13.52% year-over-year [1] - Q3 net profit was 46.4276 million yuan, down 21.46% compared to the previous year [1] - Revenue for the first three quarters was 7.566 billion yuan, reflecting an 18.28% decline [1] - Net profit for the first three quarters was 56.7048 million yuan, a significant drop of 56.67% [1] Business Segments - Diagnostic services generated revenue of 2.622 billion yuan in Q3, with ICL contributing 2.481 billion yuan [1] - Channel products business achieved revenue of 4.931 billion yuan [1] - Proprietary products business reported revenue of 284 million yuan [1]

证券代码：300244 证券简称：迪安诊断 公告编号：2025-037 迪安诊断技术集团股份有限公司 2025 年第三季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 10 月 23 日 1 巨潮资讯网网址：http://www.cninfo.com.cn/ 特此公告。 迪安诊断技术集团股份有限公司 董事会 特别提示：本公司 2025 年第三季度报告于 2025 年 10 月 24 日在中国证监 会指定的创业板信息披露网站上披露，敬请投资者注意查阅。 迪安诊断技术集团股份有限公司（以下简称"公司"）于 2025 年 10 月 22 日召开第五届董事会第十六次会议，审议通过了《关于<2025 年第三季度报告> 的议案》。为使投资者全面了解公司的经营成果、财务状况及未来发展规划，公 司《2025 年第三季度报告》于 2025 年 10 月 24 日在中国证监会指定的创业板 信息披露网站巨潮资讯网上披露，敬请投资者注意查阅。 ...

Financial Performance - The company's revenue for Q3 2025 was ¥2,629,101,734.09, a decrease of 13.52% compared to the same period last year[5] - Net profit attributable to shareholders was ¥46,427,604.81, down 21.46% year-on-year, while the net profit excluding non-recurring gains and losses was ¥44,787,340.40, a decrease of 23.94%[5] - For the first nine months of 2025, the company achieved a total revenue of ¥7,565,586,728.42, representing an 18.28% decline year-on-year[9] - Total operating revenue for the current period is ¥7,565,586,728.42, a decrease of 18.3% from ¥9,258,110,867.57 in the previous period[21] - Net profit for the current period is ¥182,010,837.30, a decline of 39.9% compared to ¥302,683,796.72 in the previous period[22] - Earnings per share (basic) for the current period is ¥0.0928, down from ¥0.2118 in the previous period[22] - The company’s total profit before tax is ¥276,089,133.22, down from ¥424,171,620.41 in the previous period, representing a decline of 34.8%[22] - The company’s total comprehensive income for the current period is ¥182,010,837.30, compared to ¥302,682,117.22 in the previous period[22] Cash Flow and Assets - The company reported a significant increase in net cash flow from operating activities, reaching ¥871,715,623.10, a rise of 1508.33% compared to the previous year[9] - Operating cash flow for the current period is ¥871,715,623.10, a significant increase from ¥54,200,047.93 in the previous period, reflecting a strong operational performance[24] - Total cash inflow from operating activities decreased to ¥8,468,610,339.97 from ¥9,601,233,221.75, indicating a decline of approximately 11.8% year-over-year[24] - Cash outflow from operating activities also decreased to ¥7,596,894,716.87 from ¥9,547,033,173.82, resulting in a reduction of about 20.4%[24] - The ending cash and cash equivalents balance is ¥1,346,814,696.43, a slight decrease from ¥1,352,553,738.03 in the previous period[25] - The company’s cash flow from operating activities reflects a robust operational strategy despite a decrease in total cash inflows[24] Shareholder Information - Total number of common shareholders at the end of the reporting period was 45,695[12] - The largest shareholder, Chen Haibin, holds 26.31% of shares, totaling 164,438,933 shares, with 76,460,000 shares pledged[12] - The company repurchased 13,880,000 shares, accounting for 2.22% of the total share capital[13] - The number of shares held by the top ten unrestricted shareholders totaled 100,000,000 shares[13] Asset and Liability Management - Total assets at the end of the reporting period were ¥14,765,016,764.23, a decrease of 6.47% from the previous year[5] - The company's total current assets decreased from CNY 11,902,542,869.23 to CNY 11,040,261,948.58, a decline of approximately 7.24%[18] - Cash and cash equivalents decreased from CNY 1,830,317,273.55 to CNY 1,372,146,968.42, a reduction of about 25%[18] - Accounts receivable decreased from CNY 7,258,897,680.33 to CNY 6,735,971,949.60, a decline of approximately 7.2%[18] - Total liabilities amount to ¥6,090,797,605.65, a decrease from ¥7,018,794,162.32 in the previous period[20] - Total equity is ¥8,674,219,158.58, down from ¥8,767,189,572.23 in the previous period[20] - The company’s long-term borrowings decreased to ¥1,348,014,472.00 from ¥1,593,720,736.00, a reduction of 15.4%[20] Operational Developments - The company added 12 new precision centers in the first three quarters, bringing the total to 102, with related business growth of 11.25%[10] - The company signed 1,504 new clients, further increasing its market share[10] - The company is advancing its AI products and digital solutions, collaborating with partners like Alibaba and Huawei Cloud, and has become a key player in the trusted data space in Hangzhou[10] - Financial expenses decreased by 36.56% during the reporting period, reflecting improved internal management efficiency[10] Research and Development - The company reported a decrease in research and development expenses to ¥169,463,374.03 from ¥225,278,980.27, a reduction of 24.8%[21]

Core Insights - The company reported a third-quarter revenue of 2.629 billion yuan, a decrease of 13.52% [1] - Net profit for the third quarter was 46.4276 million yuan, down 21.46% [1] - For the first three quarters, revenue totaled 7.566 billion yuan, reflecting an 18.28% decline [1] - Net profit for the first three quarters was 56.7048 million yuan, a significant drop of 56.67% [1] Financial Performance - Third-quarter revenue: 2.629 billion yuan, down 13.52% [1] - Third-quarter net profit: 46.4276 million yuan, down 21.46% [1] - Year-to-date revenue: 7.566 billion yuan, down 18.28% [1] - Year-to-date net profit: 56.7048 million yuan, down 56.67% [1]

Automotive Industry - The core point of the report highlights the impressive performance of the Chinese automotive industry in the first three quarters of 2025, with strong growth in new energy vehicles (NEVs) [3][4] - In the first three quarters of 2025, production and sales of NEVs exceeded 11.24 million units, representing a year-on-year growth of 35.2% and 34.9% respectively, with a penetration rate of 46.1% [4] - In September 2025, NEV production and sales reached 1.617 million and 1.604 million units, showing a month-on-month increase of 16.3% and 15%, and a year-on-year increase of 23.7% and 24.6% [4] - The export volume of automobiles in the first three quarters of 2025 increased by 14.8% year-on-year, with a total export of 4.95 million vehicles [4] - The report suggests focusing on leading companies in the NEV supply chain and those with overseas market presence, as the increasing penetration rate of NEVs will drive the collaborative development of the entire industry chain [4][5] Investment Recommendations - The report indicates that the automotive sector is experiencing a resonance phase between new product cycles and technological advancements, particularly in smart driving and smart cockpit technologies, which are expected to drive continuous sales growth [5] - Continuous policy support for automotive consumption and the rising penetration rate of NEVs provide a broad market space for vehicle manufacturers [5] - In the components sector, the rapid increase in the penetration of smart components such as smart cockpits and electric drive systems is expected to benefit related companies [5] - The report maintains an "overweight" rating for the automotive industry, recommending attention to quality companies in the sector, such as Shuanghuan Transmission and Beite Technology [5] New Materials - The report notes a slight increase of 0.05% in the rare earth magnetic materials industry, outperforming the benchmark by 2.27 percentage points [7] - The prices of rare earth concentrates have accelerated their decline, with specific price drops reported for various rare earth minerals [9] - The report highlights the need to monitor the demand side closely, as the market's just-in-time transactions are primarily driven by basic needs, with expectations for demand to improve in the coming months [10] Medical Services - The report indicates a decline of 2.48% in the pharmaceutical and biological sector, with the medical services sub-sector experiencing a significant drop of 5.21% [11][12] - The current PE ratio for the medical services sector is 34.96, with a recent decrease of 1.96 from the previous week [13][14] - The report emphasizes the potential of ADC (Antibody-Drug Conjugates) and CDMO (Contract Development and Manufacturing Organization) in the innovative drug sector, projecting significant growth in the ADC outsourcing market [15][16] - The report maintains a "buy" rating for the medical services industry, recommending attention to high-growth companies and those with improving expectations, such as WuXi AppTec and Aier Eye Hospital [17] ETF Market Overview - As of October 17, 2025, there are 1,328 ETFs in the Shanghai and Shenzhen markets, with a total asset management scale of 55,264.48 billion [19] - The report notes that the average weekly change in shares for stock ETFs was an increase of 27.63 million shares, with significant increases in bank and brokerage ETFs [20] - The report recommends focusing on the automotive, coal, and agriculture sectors within the PB-ROE framework for ETF rotation strategies, highlighting the potential for these sectors to outperform [24]

Core Insights - On October 20, Dian Diagnostics experienced a 1.00% increase in stock price with a trading volume of 99.02 million yuan [1] - The company reported a financing buy-in of 10.20 million yuan and a net financing outflow of -2.76 million yuan on the same day [1] - As of October 20, the total financing and securities lending balance for Dian Diagnostics was 610 million yuan, indicating a high level of financing activity [1] Financing Summary - On October 20, Dian Diagnostics had a financing buy-in of 10.20 million yuan, with a current financing balance of 608 million yuan, representing 6.44% of its market capitalization [1] - The financing balance is above the 70th percentile of the past year, indicating a relatively high level of financing [1] - In terms of securities lending, there were no shares repaid, with 1,200 shares sold, amounting to 18,100 yuan at the closing price [1] Company Overview - Dian Diagnostics, established on September 5, 2001, and listed on July 19, 2011, is based in Hangzhou, Zhejiang Province [1] - The company specializes in providing medical diagnostic services, focusing on outsourcing solutions for various healthcare institutions, including hospitals and health service centers [1] - The revenue composition includes 65.34% from channel products and 34.66% from diagnostic services [1] Financial Performance - As of June 30, 2025, Dian Diagnostics reported a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61% [2] - The net profit attributable to shareholders was 10.28 million yuan, reflecting a significant year-on-year decline of 85.68% [2] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.32% to 48,300, while the average number of circulating shares per person increased by 12.77% to 10,376 shares [2] - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 712 million yuan distributed over the past three years [3] - Notable institutional shareholders include Hong Kong Central Clearing Limited and new entrant招商优势企业混合A, indicating a shift in shareholder composition [3]

Core Viewpoint - The stock of Dian Diagnostics has experienced a decline recently, with a notable drop in trading volume and a significant decrease in revenue and profit year-on-year [1][2]. Financial Performance - As of June 30, 2025, Dian Diagnostics reported a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61% [2]. - The net profit attributable to shareholders was 10.2772 million yuan, reflecting a substantial year-on-year decrease of 85.68% [2]. - The stock price has increased by 35.78% year-to-date, but has seen declines of 5.81% over the last five trading days, 12.22% over the last 20 days, and 3.77% over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.32% to 48,300, while the average circulating shares per person increased by 12.77% to 10,376 shares [2]. - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 712 million yuan distributed over the last three years [3]. Institutional Holdings - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 14.7985 million shares, an increase of 3.4713 million shares from the previous period [3]. - The third-largest circulating shareholder is the newly entered招商优势企业混合A, holding 11 million shares [3]. - The seventh-largest shareholder, 南方中证1000ETF, increased its holdings by 872,500 shares to 4.6097 million shares [3].

Macro Strategy - In September, CPI decreased by 0.3% year-on-year and increased by 0.1% month-on-month, with food prices rising by 0.7% and pork prices falling by 17.0%, contributing to a 0.26 percentage point decline in CPI [2][4] - By the end of September, M2 balance reached 335.38 trillion yuan, growing by 8.4% year-on-year, while the total social financing stock was 437.08 trillion yuan, up 8.7% year-on-year [2][4] Healthcare Services Industry - The pharmaceutical and biological sector fell by 1.20%, ranking 25th among 31 primary industries, with the medical services sub-sector dropping 3.37% [6][9] - WuXi AppTec is highlighted as a CRDMO integrated platform company, with its R&D segment driving growth and D&M capacity release significantly increasing revenue per capita from 542,000 yuan in 2018 to an expected 1,118,000 yuan in 2025 [7][8] - The long-term development trend of the healthcare services industry remains positive despite recent geopolitical tensions, with a "buy" rating maintained for the sector [9] Securities Industry - The securities sector showed active performance post-holiday, with the brokerage index rising by 0.5%, outperforming the CSI 300 index by 1 percentage point [11][15] - Daily average stock trading volume reached 25.87 trillion yuan, a 19% increase from the previous period, indicating a significant recovery in trading activity [12][13] - The investment recommendation for the securities industry is to maintain an "overweight" rating, focusing on internet brokerages and firms with strong performance certainty [15] Electronic Industry - OpenAI's release of Sora 2.0 marks a significant milestone in AI applications, with the new video generation model achieving high realism and user engagement [17][19] - The electronic industry is expected to benefit from ongoing recovery in consumer electronics and AI technology advancements, maintaining an "overweight" rating [19] New Materials Industry - The rare earth magnetic materials sector increased by 10.44%, outperforming the benchmark by 8.97 percentage points, while rare earth prices showed mixed trends [21][24] - The investment outlook remains cautious, with a recommendation to maintain an "overweight" rating, focusing on upstream rare earth resource companies and downstream magnetic material firms [25] Banking Industry - Social financing growth slowed to 8.7% in September, with improvements in credit structure, particularly in long-term loans supported by policy measures [28][32] - The banking sector is expected to maintain stable performance, with a recommendation to focus on state-owned banks and regional banks for their investment value [32]

Core Insights - On October 15, 2023, Dian Diagnostics saw a stock increase of 2.02% with a trading volume of 157 million yuan, indicating positive market sentiment towards the company [1] - The company reported a financing net buy of -594.83 million yuan on the same day, suggesting a higher level of selling pressure compared to buying [1] - As of October 15, 2023, the total balance of margin trading for Dian Diagnostics was 620 million yuan, which is relatively high compared to historical levels [1] Financing Summary - On October 15, 2023, Dian Diagnostics had a financing buy amount of 13.50 million yuan, while the financing balance stood at 617 million yuan, accounting for 6.32% of its market capitalization [1] - The financing balance is above the 70th percentile of the past year, indicating a high level of leverage [1] - The company had a short selling balance of 233.67 million yuan, with a short selling volume of 14.95 million shares, which is also above the 90th percentile of the past year [1] Financial Performance - For the first half of 2025, Dian Diagnostics reported a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61% [2] - The net profit attributable to shareholders for the same period was 10.28 million yuan, reflecting a significant year-on-year decline of 85.68% [2] Shareholder Information - As of June 30, 2025, the number of shareholders for Dian Diagnostics was 48,300, a decrease of 11.32% from the previous period [2] - The average number of tradable shares per shareholder increased by 12.77% to 10,376 shares [2] - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 712 million yuan distributed in the last three years [3]

Core Points - The company announced the appointment of Fang Yan as the representative for securities affairs [2] Group 1 - The board of directors of the company approved the hiring of Fang Yan [2]